| Title |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma
|
|---|---|
| Published in |
Supportive Care in Cancer, April 2013
|
| DOI | 10.1007/s00520-013-1808-5 |
| Pubmed ID | |
| Authors |
Divaya Bhutani, Jeffrey Zonder, Jason Valent, Nishant Tageja, Lois Ayash, Abhinav Deol, Zaid Al-Kadhimi, Judith Abrams, Lawrence Lum, Voravit Ratanatharathorn, Joseph Uberti, Muneer H. Abidi |
| Abstract |
Lenalidomide (LEN) is a relatively new and very effective therapy for multiple myeloma (MM). Prior LEN therapy is associated with an increased risk of peripheral blood stem cell collection (PBSC) failure, particularly with filgrastim (G-CSF) alone. We performed a retrospective chart review of 319 consecutive MM patients who underwent apheresis to collect PBSCs for the first autologous stem cell transplant (ASCT). |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 50% |
| Canada | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 15% |
| Researcher | 5 | 15% |
| Professor > Associate Professor | 4 | 12% |
| Student > Postgraduate | 3 | 9% |
| Student > Ph. D. Student | 3 | 9% |
| Other | 9 | 26% |
| Unknown | 5 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 59% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Business, Management and Accounting | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 6 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2013.
All research outputs
#13,888,372
of 22,707,247 outputs
Outputs from Supportive Care in Cancer
#2,653
of 4,536 outputs
Outputs of similar age
#110,217
of 197,532 outputs
Outputs of similar age from Supportive Care in Cancer
#25
of 40 outputs
Altmetric has tracked 22,707,247 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,536 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,532 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.